vs

Side-by-side financial comparison of DENNY'S Corp (DENN) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $113.2M, roughly 1.8× DENNY'S Corp). DENNY'S Corp runs the higher net margin — 0.6% vs -62.0%, a 62.6% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs 1.3%). DENNY'S Corp produced more free cash flow last quarter ($16.0M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs -0.9%).

Denny's is an American table service diner-style restaurant chain. It operates over 1,400 restaurants in the United States, Canada, México, Puerto Rico, and several other international locations.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

DENN vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.8× larger
RARE
$207.3M
$113.2M
DENN
Growing faster (revenue YoY)
RARE
RARE
+24.6% gap
RARE
25.9%
1.3%
DENN
Higher net margin
DENN
DENN
62.6% more per $
DENN
0.6%
-62.0%
RARE
More free cash flow
DENN
DENN
$116.7M more FCF
DENN
$16.0M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
-0.9%
DENN

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
DENN
DENN
RARE
RARE
Revenue
$113.2M
$207.3M
Net Profit
$632.0K
$-128.6M
Gross Margin
Operating Margin
9.2%
-54.7%
Net Margin
0.6%
-62.0%
Revenue YoY
1.3%
25.9%
Net Profit YoY
-90.3%
3.5%
EPS (diluted)
$0.01
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DENN
DENN
RARE
RARE
Q4 25
$207.3M
Q3 25
$113.2M
$159.9M
Q2 25
$117.7M
$166.5M
Q1 25
$111.6M
$139.3M
Q4 24
$114.7M
$164.6M
Q3 24
$111.8M
$139.5M
Q2 24
$115.9M
$147.0M
Q1 24
$110.0M
$108.8M
Net Profit
DENN
DENN
RARE
RARE
Q4 25
$-128.6M
Q3 25
$632.0K
$-180.4M
Q2 25
$2.5M
$-115.0M
Q1 25
$326.0K
$-151.1M
Q4 24
$6.8M
$-133.2M
Q3 24
$6.5M
$-133.5M
Q2 24
$3.6M
$-131.6M
Q1 24
$4.7M
$-170.7M
Operating Margin
DENN
DENN
RARE
RARE
Q4 25
-54.7%
Q3 25
9.2%
-106.9%
Q2 25
7.3%
-64.8%
Q1 25
4.7%
-102.6%
Q4 24
12.6%
-74.3%
Q3 24
10.5%
-94.6%
Q2 24
7.9%
-79.1%
Q1 24
9.1%
-151.9%
Net Margin
DENN
DENN
RARE
RARE
Q4 25
-62.0%
Q3 25
0.6%
-112.8%
Q2 25
2.1%
-69.0%
Q1 25
0.3%
-108.5%
Q4 24
5.9%
-80.9%
Q3 24
5.8%
-95.7%
Q2 24
3.1%
-89.5%
Q1 24
4.3%
-156.8%
EPS (diluted)
DENN
DENN
RARE
RARE
Q4 25
$-1.28
Q3 25
$0.01
$-1.81
Q2 25
$0.05
$-1.17
Q1 25
$0.01
$-1.57
Q4 24
$0.13
$-1.34
Q3 24
$0.12
$-1.40
Q2 24
$0.07
$-1.52
Q1 24
$0.09
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DENN
DENN
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$-32.7M
$-80.0M
Total Assets
$502.9M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DENN
DENN
RARE
RARE
Q4 25
$421.0M
Q3 25
$202.5M
Q2 25
$176.3M
Q1 25
$1.1M
$127.1M
Q4 24
$100.0K
$174.0M
Q3 24
$2.9M
$150.6M
Q2 24
$2.8M
$480.7M
Q1 24
$2.8M
$112.3M
Total Debt
DENN
DENN
RARE
RARE
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$270.6M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
DENN
DENN
RARE
RARE
Q4 25
$-80.0M
Q3 25
$-32.7M
$9.2M
Q2 25
$-34.6M
$151.3M
Q1 25
$-36.4M
$144.2M
Q4 24
$-34.0M
$255.0M
Q3 24
$-54.5M
$346.8M
Q2 24
$-53.2M
$432.4M
Q1 24
$-55.7M
$140.3M
Total Assets
DENN
DENN
RARE
RARE
Q4 25
$1.5B
Q3 25
$502.9M
$1.2B
Q2 25
$491.1M
$1.3B
Q1 25
$488.1M
$1.3B
Q4 24
$496.3M
$1.5B
Q3 24
$461.6M
$1.5B
Q2 24
$459.9M
$1.6B
Q1 24
$460.4M
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DENN
DENN
RARE
RARE
Operating Cash FlowLast quarter
$16.0M
$-99.8M
Free Cash FlowOCF − Capex
$16.0M
$-100.8M
FCF MarginFCF / Revenue
14.1%
-48.6%
Capex IntensityCapex / Revenue
0.0%
0.5%
Cash ConversionOCF / Net Profit
25.28×
TTM Free Cash FlowTrailing 4 quarters
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DENN
DENN
RARE
RARE
Q4 25
$-99.8M
Q3 25
$16.0M
$-91.4M
Q2 25
$9.4M
$-108.3M
Q1 25
$5.0M
$-166.5M
Q4 24
$8.5M
$-79.3M
Q3 24
$6.6M
$-67.0M
Q2 24
$14.2M
$-77.0M
Q1 24
$215.0K
$-190.7M
Free Cash Flow
DENN
DENN
RARE
RARE
Q4 25
$-100.8M
Q3 25
$16.0M
$-92.7M
Q2 25
$-110.7M
Q1 25
$-167.8M
Q4 24
$-79.5M
Q3 24
$-68.6M
Q2 24
$-79.0M
Q1 24
$-193.9M
FCF Margin
DENN
DENN
RARE
RARE
Q4 25
-48.6%
Q3 25
14.1%
-58.0%
Q2 25
-66.5%
Q1 25
-120.5%
Q4 24
-48.3%
Q3 24
-49.2%
Q2 24
-53.7%
Q1 24
-178.2%
Capex Intensity
DENN
DENN
RARE
RARE
Q4 25
0.5%
Q3 25
0.0%
0.8%
Q2 25
1.5%
Q1 25
1.0%
Q4 24
0.1%
Q3 24
0.0%
1.2%
Q2 24
1.4%
Q1 24
3.0%
Cash Conversion
DENN
DENN
RARE
RARE
Q4 25
Q3 25
25.28×
Q2 25
3.79×
Q1 25
15.38×
Q4 24
1.26×
Q3 24
1.01×
Q2 24
3.97×
Q1 24
0.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DENN
DENN

Franchisor Owned Outlet$57.4M51%
Royalty$27.7M25%
Advertising$18.6M16%
Occupancy$7.7M7%
Initial And Other Fees$1.7M1%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons